Visivra Ingredients: The Six Actives Named On The Bottle

These two travel together and it is worth understanding why before anything else on the label makes sense. The macula, the few square millimetres of retina that does your reading and your face recognition, is yellow. It is yellow because it concentrates exactly three carotenoids: lutein, zeaxanthin and meso-zeaxanthin. The human body manufactures none of them. Every molecule in that yellow patch arrived through food and was then actively transported there.

That pigment does two physical jobs. It absorbs short-wavelength light before it reaches the photoreceptors, and it is an antioxidant in a tissue with one of the highest oxygen demands in the body. Both are mechanisms rather than outcomes, and mechanisms are where supplement marketing usually stops. The outcome research is narrower.

AREDS2 is the trial that put these two on shelves. It gave lutein 10 mg and zeaxanthin 2 mg a day, for a median of five years, to people who already had intermediate age-related macular degeneration. In the primary analysis lutein and zeaxanthin did not significantly reduce progression against placebo; in the pre-specified secondary analysis they did outperform beta carotene, which is why the formula was changed. That is the honest shape of the headline result, and it is a narrower claim than most eye supplement copy implies.

In eyes without disease the picture is different again. A one-year randomised trial gave lutein 10 mg and zeaxanthin 2 mg a day for one year, 115 young adults and measured macular pigment, glare disability, photostress recovery and chromatic contrast in young healthy adults. Pigment rose and some visual measures moved with it. A later meta-analysis of macular pigment against visual function found the association held across studies, most strongly for glare and contrast rather than for acuity.

A 2025 trial in heavy screen users is the closest thing to this product's own buyer: lutein 10 mg and zeaxanthin 2 mg twice a day for four months, in adults on screens eight hours a day. Note the amount. It is twice the AREDS2 figure, because it was given twice daily.

Astaxanthin is the pigment that turns salmon flesh and flamingo feathers pink. Commercially it is grown in the microalga Haematococcus pluvialis, which makes it under stress. Structurally it sits at the far end of the carotenoid family: the same long conjugated backbone as lutein, with extra oxygen groups at both ends that let the molecule span a cell membrane rather than sit inside it.

That structural point is the whole of the mechanism argument, and it is the kind of argument that sounds more conclusive than it is. What matters for a buyer is the human eye evidence, and in this ingredient's case that is one recent well-conducted trial.

The 2025 digital eye strain trial gave 4 mg of astaxanthin a day for eighty-four days, in children aged 10 to 14. Sixty-four children who spent four hours a day or more on screens, all with mild to moderate computer vision syndrome scores, randomised double-blind against placebo. The symptom questionnaire improved by about 20% more than placebo, a visual fatigue scale by 27%, and stereopsis and pupillary light reflex both moved.

Two things to hold on to. That is a real result, properly run and registered. And its participants were between ten and fourteen years old, which is not the buyer this bottle is sold to. A 2026 review of carotenoids in eye disease is a reasonable place to see how thin the adult evidence still is.

Vitamin A is the one ingredient here with an unarguable role in vision. Retinal, the aldehyde form, is the molecule that sits inside rhodopsin and physically changes shape when a photon hits it. Without it a photoreceptor cannot signal at all, which is why deficiency causes night blindness before anything else.

That is also why it is the ingredient to read most carefully, because vitamin A on a label can mean two chemically different things. Preformed vitamin A, which is retinol or retinyl palmitate, is absorbed directly and stored in the liver, and it has a genuine upper limit. Provitamin A carotenoids, principally beta carotene, are converted on demand and the body simply stops converting when it has enough.

The CARET trial gave beta carotene 30 mg plus retinyl palmitate 25,000 IU a day, in smokers and asbestos-exposed workers and was stopped early: more lung cancer, not less. The ATBC trial had already found the same thing with beta carotene 20 mg a day, in male smokers. Those two results are the reason AREDS2 removed beta carotene from the eye formula altogether.

At the other end, a 2026 systematic review of hypervitaminosis A collects what chronic excess of the preformed form does: headache, bone pain, hair and skin changes, and liver injury. the Institute of Medicine’s vitamin A chapter is the source for the adult upper limit on preformed vitamin A.

For completeness, the one place a large vitamin A dose is used deliberately in eye medicine is retinitis pigmentosa, where a four-year trial ran lutein 12 mg a day for four years, alongside vitamin A 15,000 IU a day. The Cochrane review of that practice is cautious about it. None of that is what a general eye supplement is for, and it is included here only so the scale is clear.